Skip to main content

CymaBay Therapeutics, Inc.

CBAYInactive ticker
Industry
Pharmaceutical Preparations
SEC CIK
0001042074

No open-market purchases or sales by CymaBay Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by CymaBay Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for CymaBay Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for CymaBay Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Wiggans Thomas GDirector–Mar 22, 20240
Emster Kurt VonDirector0Mar 22, 20240
Quinlan Paul TGeneral Counsel0Mar 22, 20240
Dickinson KlaraChief Regulatory Officer0Mar 22, 20240
Loewy Caroline MDirector–Mar 22, 20240
Shah SujalChief Executive Officer0Mar 22, 20240
McWherter CharlesPresident of R&D0Mar 22, 20240
Lefebvre EricDirector–Mar 22, 20240
Wills Robert JamesDirector0Mar 22, 20240
Dorling JanetDirector0Mar 22, 20240
Shantharam HarishChief Financial Officer0Mar 22, 20240
Menold DanielVice President, Finance0Jan 16, 20240
Avoro Capital Advisors LLC10% Owner–Sep 14, 20230
Aghazadeh Behzad10% Owner–Sep 14, 20230
Kim Dennis DChief Medical Officer20,000Apr 17, 20230
Stuart Lewis JChief Commercial Officer–Jan 27, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 14, 2024 (view filing)Feb 122 daysDorling JanetDirectorSSale−6.00K$31.97−$191.8K−100.0%0 after10b5-1
Jan 22, 2024 (view filing)Jan 193 daysMcWherter CharlesPresident of R&DSSale−18.4K$23.67−$435.7K−55.1%15.0K after5 lots10b5-1
Jan 16, 2024 (view filing)Jan 16Same dayMenold DanielVice President, FinanceSSale−10.0K$23.58−$235.8K−100.0%0 after10b5-1
Jan 16, 2024 (view filing)Jan 16Same dayQuinlan Paul TGeneral CounselSSale−5.00K$23.58−$117.9K−100.0%0 after
Jan 10, 2024 (view filing)Jan 10Same dayDorling JanetDirectorSSale−6.00K$23.86−$143.2K−100.0%0 after10b5-1
Dec 18, 2023 (view filing)Dec 18Same dayMcWherter CharlesPresident of R&DSSale−11.3K$21.48−$243.5K−43.0%15.0K after2 lots
Dec 15, 2023 (view filing)Dec 15Same dayMenold DanielVice President, FinanceSSale−21.5K$21.99−$472.6K−100.0%0 after2 lots10b5-1
Dec 15, 2023 (view filing)Dec 15Same dayQuinlan Paul TGeneral CounselSSale−5.00K$21.98−$109.9K−100.0%0 after
Dec 11, 2023 (view filing)Dec 11Same dayShah SujalChief Executive OfficerSSale−64.9K$20.00−$1.30M−27.5%171.3K after2 lots10b5-1
Dec 11, 2023 (view filing)Dec 11Same dayDorling JanetDirectorSSale−6.00K$20.07−$120.4K−100.0%0 after10b5-1
Nov 17, 2023 (view filing)Nov 17Same dayMcWherter CharlesPresident of R&DSSale−11.3K$18.28−$207.3K−43.1%15.0K after
Nov 17, 2023 (view filing)Nov 152 daysMenold DanielVice President, FinanceSSale0–$0–0 after10b5-1
Nov 17, 2023 (view filing)Nov 152 daysQuinlan Paul TGeneral CounselSSale−5.00K$17.38−$86.9K−100.0%0 after
Nov 14, 2023 (view filing)Nov 131 dayShah SujalChief Executive OfficerSSale−64.9K$15.89−$1.03M−27.5%171.3K after2 lots10b5-1
Nov 14, 2023 (view filing)Nov 104 daysDorling JanetDirectorSSale−7.00K$15.24−$106.7K−100.0%0 after10b5-1
Oct 18, 2023 (view filing)Oct 18Same dayMcWherter CharlesPresident of R&DSSale−21.7K$14.07−$305.9K−59.2%15.0K after
Oct 18, 2023 (view filing)Oct 162 daysMenold DanielVice President, FinanceSSale0–$0–0 after10b5-1
Oct 18, 2023 (view filing)Oct 162 daysQuinlan Paul TGeneral CounselSSale−5.00K$13.76−$68.8K−100.0%0 after
Oct 10, 2023 (view filing)Oct 91 dayShah SujalChief Executive OfficerSSale−64.9K$14.20−$921.0K−27.5%171.3K after10b5-1
Sep 29, 2023 (view filing)Sep 29Same dayEmster Kurt VonDirectorSSale−15.9K$15.68−$249.6K−15.0%90.0K after10b5-1
Sep 19, 2023 (view filing)Sep 181 dayMcWherter CharlesPresident of R&DSSale−21.7K$16.22−$352.7K−59.2%15.0K after
Sep 19, 2023 (view filing)Sep 154 daysMenold DanielVice President, FinanceSSale0–$0–0 after2 lots10b5-1
Sep 19, 2023 (view filing)Sep 154 daysQuinlan Paul TGeneral CounselSSale−53.0K$16.87−$894.1K−100.0%0 after3 lots
Sep 14, 2023 (view filing)12:53 PM ETSep 12-132 daysAvoro Capital Advisors LLC and 1 other10% OwnerSSale−300.0K$0.0103−$3.09K–950 afterDerivative4 lots
Sep 14, 2023 (view filing)12:53 PM ETSep 122 daysAvoro Capital Advisors LLC and 1 other10% OwnerPPurchase+583.8K$17.13+$10.0M–583.8K afterDerivative
Aug 18, 2023 (view filing)Aug 18Same dayMcWherter CharlesPresident of R&DSSale−21.7K$11.47−$249.4K−59.2%15.0K after
Aug 16, 2023 (view filing)Aug 151 dayMenold DanielVice President, FinanceSSale0–$0–0 after2 lots10b5-1
Aug 16, 2023 (view filing)Aug 151 dayQuinlan Paul TGeneral CounselSSale−5.00K$11.91−$59.5K−100.0%0 after
Aug 11, 2023 (view filing)Aug 92 daysMenold DanielVice President, FinanceSSale−20.9K$12.35−$258.7K−100.0%0 after10b5-1
Jul 19, 2023 (view filing)Jul 181 dayMcWherter CharlesPresident of R&DSSale−21.7K$11.43−$248.6K−59.2%15.0K after
Jul 14, 2023 (view filing)Jul 14Same dayQuinlan Paul TGeneral CounselSSale−5.00K$11.81−$59.0K−100.0%0 after
Jun 30, 2023 (view filing)Jun 30Same dayQuinlan Paul TGeneral CounselSSale−5.00K$10.05−$50.3K−100.0%0 after
Jun 21, 2023 (view filing)Jun 201 dayMcWherter CharlesPresident of R&DSSale−21.7K$8.16−$177.5K−59.2%15.0K after
May 19, 2023 (view filing)May 181 dayMcWherter CharlesPresident of R&DSSale−21.7K$9.08−$197.5K−59.2%15.0K after
May 17, 2023 (view filing)May 152 daysQuinlan Paul TGeneral CounselSSale−5.00K$10.37−$51.9K−100.0%0 after
Apr 17, 2023 (view filing)Apr 13-174 daysKim Dennis DChief Medical OfficerSSale−120.0K$9.50−$1.14M−85.7%20.0K after2 lots
Mar 30, 2023 (view filing)Mar 282 daysKim Dennis DChief Medical OfficerSSale−100$8.99−$899−0.5%20.0K after
Jan 30, 2023 (view filing)4:30 PM ETJan 264 daysAvoro Capital Advisors LLC and 1 other10% OwnerPPurchase+2.14M$7.00+$15.0M–2.14M afterDerivative
Jun 7, 2022 (view filing)Jun 61 dayShah SujalChief Executive OfficerPPurchase+51.3K$1.95+$100.0K+42.8%171.3K after
Jan 20, 2022 (view filing)Jan 191 dayKim Dennis DChief Medical OfficerPPurchase+20.0K$3.04+$60.8KNew position20.0K after
Nov 23, 2021 (view filing)4:15 PM ETNov 221 dayAvoro Capital Advisors LLC and 1 other10% OwnerPPurchase+2.50M$4.00+$10.0M–2.50M afterDerivative